NICE nixes Tarceva

The U.K.'s National Institute for Health and Clinical Excellence (NICE) concluded that Tarceva erlotinib from Roche (SWX:ROG)

Read the full 173 word article

How to gain access

Continue reading with a
two-week free trial.